SEC Form 4	
------------	--

IAIE	33	-		-			NGE	COM	1133						
m 4 or Form 5 ´ / continue. See . Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934										Estimated average burden hours per response:					
Michor Franziska							ECURSION PHARMACEUTICALS,								
3.	<u>INC.</u>   KAKA									(give title		Other ( below)	specify		
4.	<ul> <li>4. If Amendment, Date of Original Filed (Month/Day/Year)</li> <li>6. Individual or Joint/Group Filing (Check Applic Line)</li> <li>Form filed by One Reporting Person Form filed by More than One Reporting</li> </ul>										'n				
										1 613011	I				
rivativ	ve Se	curities	s Ac	quired,	Dis	posed o	of, or B	enefici	ally C	Owned					
	Execution Date,		Code (	Transaction Disposed Of (D) (Instr. 3, Code (Instr. 5)			ired (A) o nstr. 3, 4 a	r ınd	I Securities Beneficially Owned Following		Form (D) o	r Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	Amount	(A) (D)	or Pric	e	Transact	ion(s)			(	
/20/202	24			Α		30,61	8 A		(1)	30,	30,618		D		
/20/202	24			Α		15,335	5 <sup>(2)</sup> A		<b>60</b>	45,953			D		
/20/202	24	<u> </u>		Α		17,694	4 <sup>(3)</sup> A		5 <mark>0</mark>	63,647			D		
											,037		D		
										wned					
sion Cise (Month/Day/Year) Ve ( / Lise (Month/Day/Year) Sec (Month/Day/Year) (Month/Day/Year) Sec (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)	5. Number 6. Date Exercisable an of Expiration Date				able and	7. Title a of Secu Underly Derivati	ind Amou rities ing ve Securi	ount B. Price of Derivative Security (Instr. 5)		derivative Securities Beneficia Owned Following Reported	e s Illy g	Form: Direct (D) or Indirect	Beneficia Ownersh (Instr. 4)		
Code	v	(A)	(D)	Date Exercisat			Title	or Numb of	er						
Α		30,670		(5)		05/02/2033			70	(6)	30,67	0	D		
A		15,286		(7)		05/16/2033			36	(8)	15,28	6	D		
A		17,694		(9)		05/14/2034			94	(10)	17,69	4	D		
					T		Char A		T						
	AENT         Filed pure         Filed pure         2.         3.1         4.         3.11         4.         ansaction         /20/202         /20/203         /20/204         /20/205         /20/205         /20/205         /20/205         /20/205         /20/205         /20/205         /20/205         /20/205         /20/205         /20/205         /20/205	AENT OF Filed pursuan or Seci 2. Issue RECU INC. 3. Date 11/20/2 4. If Ama 4. If Ama 20/2024	AENT OF CHAI         Filed pursuant to Section 30(h)         2. Issuer Name ar         RECURSIO         INC. [RXRX         3. Date of Earliest         11/20/2024         4. If Amendment, if         if any         (Month/Day/Year)         20/2024         /20/2024	XENT OF CHANGI         Filed pursuant to Section 16(a) or Section 30(h) of the         2. Issuer Name and Tic         RECURSION P         INC. [RXRX]         3. Date of Earliest Trans         11/20/2024         4. If Amendment, Date of         mith/Day/Year)         Za. Deemed         20/2024         /20/2024	Xent of changes in         Alexa of section 30(h) of the investme         Filed pursuant to Section 16(a) of the Sor Section 30(h) of the investme         Alexa of section 30(h) of the investme         Alexa of section 30(h) of the investme         3. Date of Earliest Transaction (Mi 11/20/2024         4. If Amendment, Date of Original         inth/Day/Year)         2A. Deemed Execution Date, if any (Month/Day/Year)         ansaction of frame         2(20/2024         2(20/2024         2(20/2024         2(20/2024         2(20/2024         2(20/2024         2(20/2024         2(20/2024         2(20/2024         2(20/2024         2(20/2024         2(20/2024         2(20/2024         2(20/2024         2(20/2024         2(20/2024         2(20/2024         3(1)         5. Number of Derivative Securities Acquired (Month/D Securities Acquired (Mont	Washington, D.C. 208         AENT OF CHANGES IN BEI         Filed pursuant to Section 16(a) of the Securitor or Section 30(h) of the Investment Construction Section 30(h) of Introduction Sectin 30(h) of Introduction Section 30(h) of Intro	Washington, D.C. 20549         AENT OF CHANGES IN BENEFIC!         Filed pursuant to Section 16(a) of the Securities Exchar or Section 30(h) of the Investment Company Act         2       Issuer Name and Ticker or Trading Symbol RECURSION PHARMACEUTIC INC, [RXRX]         3. Date of Earliest Transaction (Month/Day/Year) 11/20/2024       3. Date of Earliest Transaction (Month/Day/Year) 11/20/2024         4. If Amendment, Date of Original Filed (Month/Day/Year)       3. Securities Acquired, Disposed of 80 (Month/Day/Year)       4. Securi 17ansaction 80 (Month/Day/Year)         20/2024       A       30,61         20/2024       A       15,332         20/2024       A       17,694         20/2024       A       16,332         20/2024       A       16,342         30,610       Op privative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)       5. Date Exercisable and Expiration Date (Month/Day/Year)         4. A       30,670       (5)       05/02/2033         A       15,286       (7)       05/16/2033	Washington, D.C. 20549           AENT OF CHANGES IN BENEFICIAL O           Filed pursuant to Section 16(a) of the Securities Exchange Act of or Section 30(h) of the Investment Company Act of 1940           2. Issuer Name and Ticker or Trading Symbol         RECURSION PHARMACEUTICALS, INC, [RXRX]           3. Date of Earliest Transaction (Month/Day/Year)         11/20/2024           4. If Amendment, Date of Original Filed (Month/Day/Year)         3. areaction, if any (Month/Day/Year)           ansaction         2A. Deemed Execution Date, if any (Month/Day/Year)         3. areaction, if any (Month/Day/Year)           20/2024         A         4. Securities Acquired, Disposed Of (o) (b)           20/2024         A         15,335 <sup>(2)</sup> /20/2024         A         17,694 <sup>(3)</sup>	Washington, D.C. 20549           AENT OF CHANGES IN BENEFICIAL OWNED           Filed pursuant to Section 30(h) of the Investment Company Act of 1940           2. Issuer Name and Ticker or Trading Symbol RECURSION PHARMACEUTICALS, INC, [RXRX]           3. Date of Earliest Transaction (Month/Day/Year) 11/20/2024           4. If Amendment, Date of Original Filed (Month/Day/Year) 11/20/2024           4. If Amendment, Date of Original Filed (Month/Day/Year) (Month/Day/Year)           2A. Deemed Execution Date, If any (Month/Day/Year)           2D/2024           A           4. Is Associative Securities Acquired, Disposed of, or Beneficial (Month/Day/Year)           4. Intrasection of (D) (Instr. 3, 4 and 5)           4. Transaction Code (Instr. 3, 4 and 5)           4. Sociative Securities Acquired, Disposed of, or Beneficial (Month/Day/Year)           5. Date Exercisable and Of (D) (Instr. 3, 4 and 5)           6. Date Exercisable and Of (D) (Instr. 3, 4 and 5)           7. Title and Amount Of Desposed Of (D) (Instr. 3, 4 and 5)           7. Officientarian (A           7. Disposed Of (D) (Instr. 3, 4 and 5)<	Washington, D.C. 20549           AENT OF CHANGES IN BENEFICIAL OWNERSH           Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940           2. Issuer Name and Ticker or Trading Symbol RECURSION PHARMACEUTICALS, INC. [ RXRX ]         5. Rela           3. Date of Earliest Transaction (Month/Day/Year) 11/20/2024         6. Indiv Line)           4. If Amendment, Date of Original Filed (Month/Day/Year)         6. Indiv Line)           7         7         7         7         7         7         7           10/20224         A         13,535(2)         A         \$0           20/2024         A         13,5335(2)         A         \$0           20/2024         A         13,5335(2)         A         \$0           20/2024         A         17,694(3)         A         \$0           20/2024         A         17,694(3)         A         \$0           20/2024         A         17,694(3)         A         \$0           10/202024         A         17,694(3)         A         \$0           20/20224         A         17,694(3)         A         \$0           20/2024         A         17,694(3)         A         \$0           20/2024 </td <td>ACTION CHANGES IN BENEFICIAL OWNERSHIP         Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940       5. Relationship of (Check all applic)         a.       2. Issuer Name and Ticker or Trading Symbol RECURSION PHARMACEUTICALS, INC. [ RXRX ]       5. Relationship of (Check all applic)         3. Date of Earliest Transaction (Month/Day/Year) 11/20/2024       6. Individual or J Line)         4. If Amendment, Date of Original Filed (Month/Day/Year)       6. Individual or J Line)         rtrative Securities Acquired, Disposed of, or Beneficially Owned ansaction (Month/Day/Year)       5. Amount (B)       5. Amount (B)         rtrative Securities Acquired, Disposed of (D) (Instr. 3, 4 and 5)       5. Amount (B)       5. Amount (B)       5. Amount (B)         (20/2024       A       15,335<sup>(2)</sup>       A       \$0       4.3 (20/2024       5. 3. 4 and 5.0       5. Amount (B)       5. Amount (B)<!--</td--><td>Washington, D.C. 20549           AENT OF CHANGES IN BENEFICIAL OWNERSHIP           Filed pursuant to Section 36(h) of the investment Company Act of 1934 or Section 30(h) of the investment Company Act of 1934                <ul></ul></td><td>Washington, D.C. 20549           IDENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940           Elide pursuant to Section 30(h) of the Investment Company Act of 1940           IDEC. [RXRX]           3. Date of Earliest Transaction (Month/Day/Year)           4. If Amendment, Date of Original Filed (Month/Day/Year)           First Securities Acquired, Disposed of, or Beneficially Owned ansaction (Month/Day/Year)         5. Amount of Securities Person         5. Amount of Securities Person         6. Original Filed (Month/Day/Year)           (20/2024         A         30,618         A         (i)         30,618         (i)         6. Original Filed (Month/Day/Year)           (20/2024         A         15,335<sup>(2)</sup>         A         \$0         63,647         (i)         (i)         (i)         (i)           (20/2024         A         17,094<sup>(3)</sup>         A         \$0         63,647         (i)         (i)<td>Washington, D.C. 20549           AENT OF CHANGES IN BENEFICIAL OWNERSHIP           Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940           Image: Company Act of 1940           RECURSION PHARMACEUTICALS, INC. [RXRX]         Enelationship of Reporting Person(s) to Iss Check at applicable)           Image: Company Act of 1940         Enelationship of Reporting Person(s) to Iss Check at applicable)           Image: Company Act of 1940         Enelationship of Reporting Person(s) to Iss Check at applicable)           Image: Company Act of 1940         Enelationship of Reporting Person(s) to Iss Check at applicable)           Image: Company Act of 1940         Enelationship of Reporting Person(s) to Iss Check at applicable)           Image: Company Act of 1940         Enelationship of Reporting Person(s) to Iss Check at applicable)           Image: Company Act of 0 riginal Filed (Month/Day/Year)         Enelationship of Reporting Person Person           Image: Company Act of 0 riginal Filed (Month/Day/Year)         Enelationship of Reporting Person Person           Image: Company Act of 0 riginal Filed (Month/Day/Year)         Energian Person         Source of Person           Image: Company Act of 0 riginal Filed (Month/Day/Year)         Energian Person         Source of Person           Image: Company Act of 0 riginal Filed (Month/Day/Year)         Transaction (Dig) (Instr. 4)         Source of Person         Source of Pers</td></td></td>	ACTION CHANGES IN BENEFICIAL OWNERSHIP         Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940       5. Relationship of (Check all applic)         a.       2. Issuer Name and Ticker or Trading Symbol RECURSION PHARMACEUTICALS, INC. [ RXRX ]       5. Relationship of (Check all applic)         3. Date of Earliest Transaction (Month/Day/Year) 11/20/2024       6. Individual or J Line)         4. If Amendment, Date of Original Filed (Month/Day/Year)       6. Individual or J Line)         rtrative Securities Acquired, Disposed of, or Beneficially Owned ansaction (Month/Day/Year)       5. Amount (B)       5. Amount (B)         rtrative Securities Acquired, Disposed of (D) (Instr. 3, 4 and 5)       5. Amount (B)       5. Amount (B)       5. Amount (B)         (20/2024       A       15,335 <sup>(2)</sup> A       \$0       4.3 (20/2024       5. 3. 4 and 5.0       5. Amount (B)       5. Amount (B) </td <td>Washington, D.C. 20549           AENT OF CHANGES IN BENEFICIAL OWNERSHIP           Filed pursuant to Section 36(h) of the investment Company Act of 1934 or Section 30(h) of the investment Company Act of 1934                <ul></ul></td> <td>Washington, D.C. 20549           IDENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940           Elide pursuant to Section 30(h) of the Investment Company Act of 1940           IDEC. [RXRX]           3. Date of Earliest Transaction (Month/Day/Year)           4. If Amendment, Date of Original Filed (Month/Day/Year)           First Securities Acquired, Disposed of, or Beneficially Owned ansaction (Month/Day/Year)         5. Amount of Securities Person         5. Amount of Securities Person         6. Original Filed (Month/Day/Year)           (20/2024         A         30,618         A         (i)         30,618         (i)         6. Original Filed (Month/Day/Year)           (20/2024         A         15,335<sup>(2)</sup>         A         \$0         63,647         (i)         (i)         (i)         (i)           (20/2024         A         17,094<sup>(3)</sup>         A         \$0         63,647         (i)         (i)<td>Washington, D.C. 20549           AENT OF CHANGES IN BENEFICIAL OWNERSHIP           Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940           Image: Company Act of 1940           RECURSION PHARMACEUTICALS, INC. [RXRX]         Enelationship of Reporting Person(s) to Iss Check at applicable)           Image: Company Act of 1940         Enelationship of Reporting Person(s) to Iss Check at applicable)           Image: Company Act of 1940         Enelationship of Reporting Person(s) to Iss Check at applicable)           Image: Company Act of 1940         Enelationship of Reporting Person(s) to Iss Check at applicable)           Image: Company Act of 1940         Enelationship of Reporting Person(s) to Iss Check at applicable)           Image: Company Act of 1940         Enelationship of Reporting Person(s) to Iss Check at applicable)           Image: Company Act of 0 riginal Filed (Month/Day/Year)         Enelationship of Reporting Person Person           Image: Company Act of 0 riginal Filed (Month/Day/Year)         Enelationship of Reporting Person Person           Image: Company Act of 0 riginal Filed (Month/Day/Year)         Energian Person         Source of Person           Image: Company Act of 0 riginal Filed (Month/Day/Year)         Energian Person         Source of Person           Image: Company Act of 0 riginal Filed (Month/Day/Year)         Transaction (Dig) (Instr. 4)         Source of Person         Source of Pers</td></td>	Washington, D.C. 20549           AENT OF CHANGES IN BENEFICIAL OWNERSHIP           Filed pursuant to Section 36(h) of the investment Company Act of 1934 or Section 30(h) of the investment Company Act of 1934 <ul></ul>	Washington, D.C. 20549           IDENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940           Elide pursuant to Section 30(h) of the Investment Company Act of 1940           IDEC. [RXRX]           3. Date of Earliest Transaction (Month/Day/Year)           4. If Amendment, Date of Original Filed (Month/Day/Year)           First Securities Acquired, Disposed of, or Beneficially Owned ansaction (Month/Day/Year)         5. Amount of Securities Person         5. Amount of Securities Person         6. Original Filed (Month/Day/Year)           (20/2024         A         30,618         A         (i)         30,618         (i)         6. Original Filed (Month/Day/Year)           (20/2024         A         15,335 <sup>(2)</sup> A         \$0         63,647         (i)         (i)         (i)         (i)           (20/2024         A         17,094 <sup>(3)</sup> A         \$0         63,647         (i)         (i) <td>Washington, D.C. 20549           AENT OF CHANGES IN BENEFICIAL OWNERSHIP           Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940           Image: Company Act of 1940           RECURSION PHARMACEUTICALS, INC. [RXRX]         Enelationship of Reporting Person(s) to Iss Check at applicable)           Image: Company Act of 1940         Enelationship of Reporting Person(s) to Iss Check at applicable)           Image: Company Act of 1940         Enelationship of Reporting Person(s) to Iss Check at applicable)           Image: Company Act of 1940         Enelationship of Reporting Person(s) to Iss Check at applicable)           Image: Company Act of 1940         Enelationship of Reporting Person(s) to Iss Check at applicable)           Image: Company Act of 1940         Enelationship of Reporting Person(s) to Iss Check at applicable)           Image: Company Act of 0 riginal Filed (Month/Day/Year)         Enelationship of Reporting Person Person           Image: Company Act of 0 riginal Filed (Month/Day/Year)         Enelationship of Reporting Person Person           Image: Company Act of 0 riginal Filed (Month/Day/Year)         Energian Person         Source of Person           Image: Company Act of 0 riginal Filed (Month/Day/Year)         Energian Person         Source of Person           Image: Company Act of 0 riginal Filed (Month/Day/Year)         Transaction (Dig) (Instr. 4)         Source of Person         Source of Pers</td>	Washington, D.C. 20549           AENT OF CHANGES IN BENEFICIAL OWNERSHIP           Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940           Image: Company Act of 1940           RECURSION PHARMACEUTICALS, INC. [RXRX]         Enelationship of Reporting Person(s) to Iss Check at applicable)           Image: Company Act of 1940         Enelationship of Reporting Person(s) to Iss Check at applicable)           Image: Company Act of 1940         Enelationship of Reporting Person(s) to Iss Check at applicable)           Image: Company Act of 1940         Enelationship of Reporting Person(s) to Iss Check at applicable)           Image: Company Act of 1940         Enelationship of Reporting Person(s) to Iss Check at applicable)           Image: Company Act of 1940         Enelationship of Reporting Person(s) to Iss Check at applicable)           Image: Company Act of 0 riginal Filed (Month/Day/Year)         Enelationship of Reporting Person Person           Image: Company Act of 0 riginal Filed (Month/Day/Year)         Enelationship of Reporting Person Person           Image: Company Act of 0 riginal Filed (Month/Day/Year)         Energian Person         Source of Person           Image: Company Act of 0 riginal Filed (Month/Day/Year)         Energian Person         Source of Person           Image: Company Act of 0 riginal Filed (Month/Day/Year)         Transaction (Dig) (Instr. 4)         Source of Person         Source of Pers	

## Explanation of Responses:

1. (1) Received in exchange for [] ordinary shares of Exscientia plc ("Exscientia") in connection with the acquisition of the entire issued and to be issued share capital of Exscientia by Recursion Pharmaceuticals, Inc. ("Recursion") on November 20, 2024 (the "Transaction"). The last closing price on The Nasdaq Stock Market prior to the effective time of the Transaction of (a) the American Depositary Shares ("ADSs") representing ordinary shares of Exscientia was \$4.84 per ADS, and (b) Recursion's Class A common stock was \$6.27 per share.

2. Represents restricted stock units ("RSUs") that were exchanged in connection with the Transaction, each RSU representing the right to receive one share of Class A common stock of Recursion. The RSUs vest in equal quarterly installments beginning on November 3, 2024 and continuing through May 3, 2026, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates. 3. Represents RSUs that were exchanged in connection with the Transaction, each RSU representing the right to receive one share of Class A common stock of Recursion. The RSUs will vest on May 15, 2025, subject to the Reporting Person continuing to be a service provider through the applicable vesting date.

4. Represents a grant of restricted stock units automatically granted pursuant to Recursion's Outside Director Compensation Policy. The restricted stock units will vest as to 1/3rd of the shares subject to the award on the first three anniversaries of November 20, 2024, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates.

5. Options vest and become exercisable in equal quarterly installments over a three year period beginning May 3, 2023, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates.

6. Received in the Transaction in exchange for a share option to acquire 39,683 Exscientia ordinary shares for \$5.09 per share.

7. Options vest and become exercisable on May 17, 2024, subject to the Reporting Person continuing to be a service provider through the applicable vesting date.

8. Received in the Transaction in exchange for a share option to acquire 19,778 Exscientia ordinary shares for \$5.67 per share.

9. Options vest and become exercisable on May 15, 2025, subject to the Reporting Person continuing to be a service provider through the applicable vesting date.

10. Received in the Transaction in exchange for a share option to acquire 22,894 Exscientia ordinary shares for \$5.13 per share.

11. Represents a grant of options automatically granted pursuant to Recursion's Outside Director Compensation Policy. The shares subject to this option will vest and become exercisable as to 1/3rd of the shares subject to the award on the first three anniversaries of November 20, 2024, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates.

Remarks:

Jonathan D. Golightly,

attorney-in-fact

11/22/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.